Nerlynx (Neratinib Maleate) Patent Expiration, LOE Window & CMS Spending
Nerlynx (Neratinib Maleate) by Puma Biotechnology: FDA Orange Book core substance LOE 2030-12-29 (last listed 2031-07-18), 0 AB generics, $60.6M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Puma Biotechnology |
| FDA Application & Pathway | N208051 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2030-12-29 |
| Last Listed Patent or Exclusivity Date | 2031-07-18 |
| Orange Book Patents (*PED Extensions) | 9 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $60.6M |
| 2024 Medicare Part D Spend | $38.4M |
| 2024 Medicaid Spend | $22.2M |
| Reported Wholesale Price Change (CA SB 17) | 8 WAC filings (max 24.0% 2-yr change) |